Durata Therapeutics announced that Paul A. Friedman, M.D. was elected to its Board of Directors at the company's 2013 Annual Meeting of Stockholders. The company also announced the departure of Dr. Dov Goldstein from its Board, effective as of this meeting. Dr. Goldstein did not stand for re-election. Dr. Friedman has served as President and Chief Executive Officer and member of the Board of Directors of Incyte Corporation. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories.

Durata Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the period, the company reported operating loss of $15,426,000 against $8,260,000 a year ago. Loss before income tax expense was $15,519,000 against $8,258,000 a year ago. Net loss was $15,767,000 against $8,258,000 a year ago. Basic and diluted net loss per common share was $0.86 against $132.12 a year ago.

Durata Therapeutics, Inc., Q1 2013 Earnings Call, May 09, 2013